The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.

“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D. 
 
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
 

Related News Articles

Blog
My paternal grandmother was born in 1913 as the youngest of five children and the only girl. She had three sons and no daughters. When I arrived, I was the…
Blog
I was raised by my mother, who was a nurse, and an elder sister, who both prioritized education. During a visit to Kentucky State University, I was inspired to…
Headline
The AHA and other founding members of the Common Health Coalition March 13 committed to action in four priority areas: coordination between health care and…
Headline
Hospital and health system leaders March 7 received an email from the AHA and its Institute for Diversity and Health Equity reminding them to participate in…
Chairperson's File
Communication. Teamwork. Unity. That’s what helps drive health care innovation, accelerates health equity, improves health outcomes and advances health in our…
Headline
Fred Hobby, former president and CEO of the Institute for Diversity in Health Management, shares his thoughts on the current state of health equity efforts and…